Drug · DIN 02441152
KEYTRUDA
FOR I.V. INFUSION. SINGLE-USE VIAL
No: no longer authorized
The company stopped selling it and its DIN was cancelled. A cancellation is most often a business decision; the record does not say why.
Status Cancelled Post Market since December 4, 2019; first marketed June 1, 2015.
- Drug Identification Number (DIN)
- 02441152
- Company (DIN owner)
- Merck Canada IncKirkland, Quebec, Canada
- Schedule
- Schedule D; Prescription
- Dosage form
- Powder For Solution
- Route
- Intravenous
- Therapeutic class (ATC)
- Pembrolizumab L01FF02
- Class
- Human
- Record last updated
- August 13, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| PEMBROLIZUMAB | 50 MG | VIAL |
Notices of Compliance
Health Canada approvals that name this DIN.
- May 19, 2015: NOC 16911New Drug Submission (NDS)
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “keytruda”. A notice may cover another product or only some lots: read it to see what it covers.
- Keytruda (2019-04-23)April 23, 2019 · Drugs · Product safety · Type III
- KEYTRUDA (pembrolizumab) - Risk of Severe Skin Reactions: Stevens-Johnson Syndrome and Toxic Epidermal NecrolysisMarch 20, 2017 · Biologic or vaccine
Other DINs named KEYTRUDA
- DIN 02456869 · Marketed